Methacetin breath test in patients with cirrhosis

Completed

• Conditions: Cirrhosis; Digestive System

• Registration Number: ISRCTN11497545
• Lead Sponsor: Health Research Council of Mexican Institute of Social Security

Brief Summary

2017 results in https://www.ncbi.nlm.nih.gov/pubmed/28649974

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2016-12-17
• Study Start: 2017-03-02
• Last Update Posted: 27 August 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 123

Inclusion Criteria

1. Age above 18 years
2. Diagnosis of decompensated cirrhosis based on history of present illness, clinical and biochemical findings combined with ultrasonographic results, plus liver biopsy when possible

Exclusion Criteria

Hepatocarcinoma

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Survival is assessed through patient follow ups at least every 6 months for up to 3 years with analysis performed by the Kaplan-Meier method<br>2. The optimal cut-off point for predicting mortality to base line 13C-MetOx obtained by 13C-methacetin breath test within 3 years

Secondary Outcome Measures

Name	Time	Method
The optimal cut-off point for predicting mortality to base line Child-Pugh (CP) and Meld Indexes within 3 years.